Trials / Completed
CompletedNCT00545324
First Step With Singulair® Therapy (0476-323)
A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma "To Low Dose" Inhaled Corticosteroid Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 399 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks | |
| DRUG | Comparator: Fluticasone / Duration of Treatment: 6 Weeks |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-12-01
- Completion
- 2003-12-01
- First posted
- 2007-10-17
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00545324. Inclusion in this directory is not an endorsement.